Geron Corp (GERN)
3.93
-0.02
(-0.51%)
USD |
NASDAQ |
May 03, 16:00
3.925
0.00 (0.00%)
After-Hours: 20:00
Geron Research and Development Expense (Quarterly): 29.37M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 29.37M |
| December 31, 2023 | 32.91M |
| September 30, 2023 | 29.43M |
| June 30, 2023 | 35.49M |
| March 31, 2023 | 27.22M |
| December 31, 2022 | 28.21M |
| September 30, 2022 | 24.60M |
| June 30, 2022 | 20.61M |
| March 31, 2022 | 22.10M |
| December 31, 2021 | 24.15M |
| September 30, 2021 | 18.53M |
| June 30, 2021 | 21.94M |
| March 31, 2021 | 21.11M |
| December 31, 2020 | 16.23M |
| September 30, 2020 | 13.61M |
| June 30, 2020 | 10.84M |
| March 31, 2020 | 10.80M |
| December 31, 2019 | 24.92M |
| September 30, 2019 | 11.11M |
| June 30, 2019 | 10.13M |
| March 31, 2019 | 5.906M |
| December 31, 2018 | 5.081M |
| September 30, 2018 | 2.707M |
| June 30, 2018 | 3.204M |
| March 31, 2018 | 2.44M |
| Date | Value |
|---|---|
| December 31, 2017 | 2.523M |
| September 30, 2017 | 2.637M |
| June 30, 2017 | 2.499M |
| March 31, 2017 | 3.374M |
| December 31, 2016 | 4.12M |
| September 30, 2016 | 4.319M |
| June 30, 2016 | 4.575M |
| March 31, 2016 | 5.033M |
| December 31, 2015 | 3.982M |
| September 30, 2015 | 4.05M |
| June 30, 2015 | 4.812M |
| March 31, 2015 | 4.987M |
| December 31, 2014 | 4.351M |
| September 30, 2014 | 5.994M |
| June 30, 2014 | 5.151M |
| March 31, 2014 | 5.211M |
| December 31, 2013 | 5.089M |
| September 30, 2013 | 5.338M |
| June 30, 2013 | 4.807M |
| March 31, 2013 | 7.999M |
| December 31, 2012 | 11.80M |
| September 30, 2012 | 11.68M |
| June 30, 2012 | 12.78M |
| March 31, 2012 | 15.11M |
| December 31, 2011 | 19.67M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
10.13M
Minimum
Jun 2019
35.49M
Maximum
Jun 2023
21.67M
Average
22.02M
Median
Research and Development Expense (Quarterly) Benchmarks
| Madrigal Pharmaceuticals Inc | 70.64M |
| SELLAS Life Sciences Group Inc | 5.097M |
| Johnson & Johnson | 3.542B |
| Pfizer Inc | 2.493B |
| Immuneering Corp | 11.91M |